Notice was on their website under events for quite a while now..
So it's not new..
What is nice is that it is being held in New York so should be well attended.
Rare is a relative term.. Few people having the disease and cost recovery was the driving
force behind enacting this Designation. Being legally able to prescribe 2-73 NOW is
what is needed. By virtue of rarity there can not be a large scale study for approvals. The 32
patients should satisfy the threshold of acceptability of approval. Any compensations would
be more than offset by reductions in patient care costs.
Orphan Drug Status implies that the drug is experimental but available.
There is no warranty of benefit but the drug has been found to be effective and without doing harm.
Breakthrough Therapy Designation implies that the drug has gone through trials and found to be
effective.. an implies warranty of benefit.
In the case of 2-73 the doctor prescribing under ODS would be assuming more risk than under
BTD. However the side effects profile is so low on 2-73 that the risk is below many of their FDA approved drugs that they prescribe now.
It is just paperwork.. 48hours, tops..
Anavex should apply for Orphan Drug status for 2-73. It satisfies the requirement of fills the need
for an unmet need. No current drug on the market cures alzheimer's. Doctors would then
be able to prescribe it while waiting for Phase 3 to be completed.
Should be a brought up as a topic at May 6 Annual meeting..
Sentiment: Strong Buy
Contact the American Alzheimer's organization and find a doctor that will prescribe the 3-71
Still true, are you giving the gift to crooks or getting the gift from criminal shorts.?.
Right idea, wrong order.
Test results before Investor Conference, attendees would not like to be accused of inside info.
Plus all of the Investors will be asking about it. .. note the increase in institutional ownership.
Investors give blessings for partnership which is announced at Health Conference.
Why would a partner involve themselves without firm data?
I guess I just do not view Missling's announcement of the location as written in stone as others.
AF is a shill.. No one would spend that much time or effort without compensation.
He says buy..his employers are selling.
He says sell..his employers are buying.
He runs a mix of shill analysis and actual analysis just to keep out of jail.
2 maybe 3 news events before 5/20...
Plus maybe some additional media...
Had to buy 15 of those on open this AM.
Hope to sell at $4
Sentiment: Strong Buy
Call TD Ameritrade. Over the years many posters have complained about Scottrade.
Way back it herbal medicine, cause and effect was about all there was.
Culpeper's 1640 herbal guide is a good reference.
It worked or it didn't.. From all of the patients wanting to stay with 2-73 I would say it worked.
If a partnership or buyout is in the works, the partner or buyer could want their own 3rd party
analysis.. Thus twice the wait. Also if results are much better than expected then they
may go back farther upstream on the numbers evaluation.
Researchers at the University of California at Irvine (UCI) said that's exactly what they were doing when they discovered how to increase the tensile strength of nanowires that could be used to make lithium-ion batteries last virtually forever. Researchers have pursued using nanowires in batteries for years because the filaments, thousands of times thinner than a human hair, are highly conductive and have a large surface area for the storage and transfer of electrons. The problem they have encountered, however, is that nanowires are also extremely fragile and don't hold up well to repeated discharging and recharging, known as "cycling." For example, in a typical lithium-ion battery, they expand and grow brittle, which leads to cracking. UCI doctoral candidate Mya Le Thai solved the brittleness condumdrum by coating a gold nanowire in a manganese dioxide shell and encasing the assembly in an electrolyte made of a Plexiglas-like gel
If I had a need to treat for Alzheimer's, then I would strongly lien towards getting an initial shot
of IL-33 with maintenance dosage of 2-73 or 3-71.
Worrying about IL-33 therapy replacing 2-73 to me would seem unlikely.
If fact, using them together could accelerate the use of 2-73.
IL-33 helps to dissolve the plaque for an initial removal.
2-73 reduces the causes of plaque formation and helps keep the nerve cells healthy.
Seems like they are cleaning out the stops before the company sends a e-mail
PR out to those who have expressed information from the company..